том 31 издание 5 страницы 173-179

A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies

Тип публикацииJournal Article
Дата публикации2018-05-01
scimago Q1
wos Q2
БС3
SJR1.229
CiteScore5.7
Impact factor3.4
ISSN17410126, 17410134
Biochemistry
Molecular Biology
Biotechnology
Bioengineering
Краткое описание
A novel dual-cytokine-antibody fusion protein, consisting of an antibody directed against CD38 [a tumor-associated antigen mainly expressed on the surface of multiple myeloma (MM) cells], simultaneously fused to both tumor necrosis factor ligand superfamily member 10 (TRAIL) and interleukin-2 (IL2), was designed, expressed and purified to homogeneity. The novel fusion protein, termed IL2-αCD38-αCD38-scTRAIL, was able to selectively recognize its cognate antigen expressed on the surface of MM and lymphoma cell lines, as evidenced by flow cytometry analysis. Moreover, the targeted version of TRAIL was able to induce cancer cell death in vitro, both with MM cell lines and with fresh isolates from the bone marrow of MM patients. The experiments provide a rationale for possible future applications of IL2-αCD38-αCD38-scTRAIL for the treatment of patients with MM or other CD38-positive malignancies.
Найдено 
Найдено 

Топ-30

Журналы

1
2
Frontiers in Immunology
2 публикации, 13.33%
Journal of Clinical Medicine
1 публикация, 6.67%
Cellular and Molecular Life Sciences
1 публикация, 6.67%
Scientific Reports
1 публикация, 6.67%
Antibodies
1 публикация, 6.67%
Journal of Controlled Release
1 публикация, 6.67%
Acta Pharmaceutica Sinica B
1 публикация, 6.67%
International Journal of Cancer
1 публикация, 6.67%
OncoTargets and Therapy
1 публикация, 6.67%
Biotechnology Advances
1 публикация, 6.67%
Cancer Medicine
1 публикация, 6.67%
Russian Chemical Reviews
1 публикация, 6.67%
1
2

Издатели

1
2
3
Elsevier
3 публикации, 20%
MDPI
2 публикации, 13.33%
Frontiers Media S.A.
2 публикации, 13.33%
Springer Nature
2 публикации, 13.33%
Cold Spring Harbor Laboratory
2 публикации, 13.33%
Wiley
2 публикации, 13.33%
Taylor & Francis
1 публикация, 6.67%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 6.67%
1
2
3
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
15
Поделиться
Цитировать
ГОСТ |
Цитировать
De Luca R. et al. A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies // Protein Engineering, Design and Selection. 2018. Vol. 31. No. 5. pp. 173-179.
ГОСТ со всеми авторами (до 50) Скопировать
De Luca R., Kachel P., Kropivsek K., Snijder B., Manz M., Neri D. A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies // Protein Engineering, Design and Selection. 2018. Vol. 31. No. 5. pp. 173-179.
RIS |
Цитировать
TY - JOUR
DO - 10.1093/protein/gzy015
UR - https://doi.org/10.1093/protein/gzy015
TI - A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies
T2 - Protein Engineering, Design and Selection
AU - De Luca, Roberto
AU - Kachel, Paul
AU - Kropivsek, Klara
AU - Snijder, B.
AU - Manz, MG
AU - Neri, Dario
PY - 2018
DA - 2018/05/01
PB - Oxford University Press
SP - 173-179
IS - 5
VL - 31
PMID - 29982719
SN - 1741-0126
SN - 1741-0134
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2018_De Luca,
author = {Roberto De Luca and Paul Kachel and Klara Kropivsek and B. Snijder and MG Manz and Dario Neri},
title = {A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies},
journal = {Protein Engineering, Design and Selection},
year = {2018},
volume = {31},
publisher = {Oxford University Press},
month = {may},
url = {https://doi.org/10.1093/protein/gzy015},
number = {5},
pages = {173--179},
doi = {10.1093/protein/gzy015}
}
MLA
Цитировать
De Luca, Roberto, et al. “A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies.” Protein Engineering, Design and Selection, vol. 31, no. 5, May. 2018, pp. 173-179. https://doi.org/10.1093/protein/gzy015.